Author
A. Humpe
Bio: A. Humpe is an academic researcher from University of Göttingen. The author has contributed to research in topics: Transplantation & Leukapheresis. The author has an hindex of 12, co-authored 24 publications receiving 448 citations.
Papers
More filters
TL;DR: The data suggest that alloimmunization in patients with a negative risk history can be prevented by the exclusive use of leukodepleted blood components.
Abstract: The use of leukocyte-depleted blood components has become the standard therapy for multiply transfused patients during the past few years, as a measure to reduce the frequency of alloimmunization and refractoriness. We assessed frequency and causes of refractoriness, defined as a repeated 24-h post-transfusion platelet count below 20,000/microliters, in 145 consecutive patients who received three or more single-donor platelet concentrates during a 1-year period. Flow-cytometric detection of anti-platelet antibodies and a glycoprotein-specific ELISA were applied for the diagnosis of alloimmunization. Forty patients (27.6%) had at least one episode of refractoriness. In 25 of these 40 patients (62.5%), nonimmune factors (fever, sepsis, coagulopathy, splenomegaly) alone were the cause. In 15 refractory patients alloantibodies were detected. In seven patients (17.5%), alloimmunization alone caused an inadequate transfusion response, while in eight refractory patients (20.0%) alloimmunization and fever or sepsis were present. HLA antibodies were detected in 17 patients (11.7%); three patients (2%) had platelet-specific antibodies in addition to HLA antibodies; in two patients panreactive platelet antibodies were detectable. All 17 patients had a history of previous transfusions or pregnancy. We did not observe primary immunization in patients transfused exclusively with filtered (leukodepleted) blood products. Our data suggest that alloimmunization in patients with a negative risk history can be prevented by the exclusive use of leukodepleted blood components.
107 citations
TL;DR: A good correlation was determined between the variables used for characterization of peripheral blood progenitor cells–the number of CD34+ cells and the number of CFU‐GM–was observed, and a viability below 50 percent predicted a high loss of in vitro proliferative capacity, while a viability above 50 percent did not correlate with a high ratio of CF U‐GM from after and before cryopreservation.
46 citations
TL;DR: To allow cost‐effective RNA testing with NAT techniques, the national authorities of several countries have planned or already introduced tests of mixed specimens, that is, plasma pools.
37 citations
TL;DR: This data indicates that trypan blue exclusion staining is probably the most frequently applied method for assessment of viability in peripheral blood progenitor cell grafts after cryopreservation.
36 citations
TL;DR: A prospective, randomized crossover trial was performed to evaluate the influence of leukapheresis volume—that is, large versus normal—on serum electrolytes, platelet count, and other coagulation measures in 25 patients with breast cancer and 14 patients with non‐Hodgkin's lymphoma.
31 citations
Cited by
More filters
TL;DR: The institution of blood-screening measures in developed countries has decreased the risk of transfusion-associated hepatitis to a negligible level, but new cases continue to occur mainly as a result of injection-drug use and, to a lesser degree, through other means of percutaneous or mucous-membrane exposure.
Abstract: Hepatitis C virus (HCV) infects an estimated 170 million persons worldwide and thus represents a viral pandemic, one that is five times as widespread as infection with the human immunodeficiency virus type 1 (HIV-1). The institution of blood-screening measures in developed countries has decreased the risk of transfusion-associated hepatitis to a negligible level, but new cases continue to occur mainly as a result of injection-drug use and, to a lesser degree, through other means of percutaneous or mucous-membrane exposure. Progression to chronic disease occurs in the majority of HCV-infected persons, and infection with the virus has become the main indication . . .
2,966 citations
TL;DR: The use of flow cytometry in the clinical laboratory has grown substantially in the past decade due in part to the development of smaller, user-friendly, less-expensive instruments and a continuous increase in the number of clinical applications.
Abstract: The use of flow cytometry in the clinical laboratory has grown substantially in the past decade. This is attributable in part to the development of smaller, user-friendly, less-expensive instruments and a continuous increase in the number of clinical applications. Flow cytometry measures multiple characteristics of individual particles flowing in single file in a stream of fluid. Light scattering at different angles can distinguish differences in size and internal complexity, whereas light emitted from fluorescently labeled antibodies can identify a wide array of cell surface and cytoplasmic antigens. This approach makes flow cytometry a powerful tool for detailed analysis of complex populations in a short period of time. This report reviews the general principles in flow cytometry and selected applications of flow cytometry in the clinical hematology laboratory.
492 citations
TL;DR: The genetic basis, prevalent clinical manifestations, and management of recessively inherited coagulation disorders from Italy and Iran, a country with a high rate of recessive diseases due to the custom of consanguineous marriages are reviewed.
443 citations
TL;DR: This poster presents a state-of-the-art virtual reality simulation system that allows for real-time monitoring of the response of the immune system to treatments such as chemotherapy.
Abstract: The demand for platelets in England was stable at around 220,000 adult therapeutic doses (ATD) per year until 2007/8 at which point demand has increased year on year to 275,000 ATD in 2014/15, an increase of 25%. Similar rises in demand have been seen in Australia and the United States. A recent review which considered causes for this dramatic rise identified that an ageing population and an increase in the incidence of haematological malignancies (with increased treatment intensity, duration and survival) accounted for most of this change (Estcourt 2014). This guideline aims to provide practical advice on platelet transfusions to help clinicians to decide when support is expected to be beneficial and to reduce inappropriate use.
418 citations
Memorial Sloan Kettering Cancer Center1, Medical University of South Carolina2, Washington University in St. Louis3, Oregon Health & Science University4, Virginia Commonwealth University5, Yale University6, Carolinas Healthcare System7, University of Texas MD Anderson Cancer Center8, Stanford University9, Intermountain Healthcare10, University of Illinois at Chicago11, Harvard University12, University of Florida13, Ohio State University14
TL;DR: A panel of experts convened to discuss the currently available data on autologous hematopoietic stem cell mobilization and transplantation and to devise guidelines to optimize mobilization strategies.
287 citations